Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Annual Meeting of Stockholders
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • COVID-19 Long-Haulers
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
  • Nonalcoholic Steatohepatitis (NASH)
  • Triple-Negative Breast Cancer
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Leronlimab/Receptor Occupancy - Published

Results from Part Two of Phase 2 NASH Clinical Trial

Oncology Presentation

Article mentioning leronlimab’s mechanism of action

Leronlimab latest published paper

 

Sitemap

CytoDyn Inc. Sitemap

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2022 CytoDyn Inc. All Rights Reserved.
  • Twitter
  • Facebookj
Privacy Policy Disclaimer Sitemap